Penetration of efavirenz into the male genital tract: Drug concentrations and antiviral activity in semen and blood of HIV-1-infected men

Stephen Taylor; Helen Reynolds; Caroline A. Sabin; Susan M. Drake; David J. White; David J. Back; Deenan Pillay

doi:10.1097/00002030-200110190-00022

Penetration of efavirenz into the male genital tract: Drug concentrations and antiviral activity in semen and blood of HIV-1-infected men

Stephen Taylor^*
, Helen Reynolds
, Caroline A. Sabin
, Susan M. Drake
, David J. White
, David J. Back
, Deenan Pillay

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

36 Citations (Scopus)

Abstract

Efavirenz is a potent non-nucleoside reverse transcriptase inhibitor, licensed for the treatment of HIV-1. Data on sanctuary site penetration are limited. Therefore, we measured efavirenz concentrations in the blood and semen of 19 HIV-1-positive men and found concentrations in seminal plasma averaged 10% of those in blood plasma. Furthermore, seminal plasma viral loads were suppressed by 24 weeks of therapy in all patients. These data suggest that efavirenz-containing regimens have antiviral activity within the male genital tract.

Original language	English
Pages (from-to)	2051-2053
Number of pages	3
Journal	AIDS
Volume	15
Issue number	15
DOIs	https://doi.org/10.1097/00002030-200110190-00022
Publication status	Published - 19 Oct 2001
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1097/00002030-200110190-00022

Cite this

@article{9e5200d4fb76491e85edc8d0ec037647,

title = "Penetration of efavirenz into the male genital tract: Drug concentrations and antiviral activity in semen and blood of HIV-1-infected men",

abstract = "Efavirenz is a potent non-nucleoside reverse transcriptase inhibitor, licensed for the treatment of HIV-1. Data on sanctuary site penetration are limited. Therefore, we measured efavirenz concentrations in the blood and semen of 19 HIV-1-positive men and found concentrations in seminal plasma averaged 10\% of those in blood plasma. Furthermore, seminal plasma viral loads were suppressed by 24 weeks of therapy in all patients. These data suggest that efavirenz-containing regimens have antiviral activity within the male genital tract.",

author = "Stephen Taylor and Helen Reynolds and Sabin, \{Caroline A.\} and Drake, \{Susan M.\} and White, \{David J.\} and Back, \{David J.\} and Deenan Pillay",

year = "2001",

month = oct,

day = "19",

doi = "10.1097/00002030-200110190-00022",

language = "English",

volume = "15",

pages = "2051--2053",

journal = "AIDS",

issn = "0269-9370",

publisher = "Lippincott Williams and Wilkins",

number = "15",

}

TY - JOUR

T1 - Penetration of efavirenz into the male genital tract

T2 - Drug concentrations and antiviral activity in semen and blood of HIV-1-infected men

AU - Taylor, Stephen

AU - Reynolds, Helen

AU - Sabin, Caroline A.

AU - Drake, Susan M.

AU - White, David J.

AU - Back, David J.

AU - Pillay, Deenan

PY - 2001/10/19

Y1 - 2001/10/19

N2 - Efavirenz is a potent non-nucleoside reverse transcriptase inhibitor, licensed for the treatment of HIV-1. Data on sanctuary site penetration are limited. Therefore, we measured efavirenz concentrations in the blood and semen of 19 HIV-1-positive men and found concentrations in seminal plasma averaged 10% of those in blood plasma. Furthermore, seminal plasma viral loads were suppressed by 24 weeks of therapy in all patients. These data suggest that efavirenz-containing regimens have antiviral activity within the male genital tract.

AB - Efavirenz is a potent non-nucleoside reverse transcriptase inhibitor, licensed for the treatment of HIV-1. Data on sanctuary site penetration are limited. Therefore, we measured efavirenz concentrations in the blood and semen of 19 HIV-1-positive men and found concentrations in seminal plasma averaged 10% of those in blood plasma. Furthermore, seminal plasma viral loads were suppressed by 24 weeks of therapy in all patients. These data suggest that efavirenz-containing regimens have antiviral activity within the male genital tract.

UR - https://www.scopus.com/pages/publications/0035914039

U2 - 10.1097/00002030-200110190-00022

DO - 10.1097/00002030-200110190-00022

M3 - Article

C2 - 11600838

AN - SCOPUS:0035914039

SN - 0269-9370

VL - 15

SP - 2051

EP - 2053

JO - AIDS

JF - AIDS

IS - 15

ER -

Penetration of efavirenz into the male genital tract: Drug concentrations and antiviral activity in semen and blood of HIV-1-infected men

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this